Key Insights

Highlights

Treatment Research

3 treatments under study, led by Midazolam

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 1 (2)

Trial Status

Recruiting1
Unknown1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07289776Phase 1RecruitingPrimary

A First-in-human Trial of GRT7041 in Healthy Participants

SYF87b07bd20d104f2da6ce56c3052f44a8Phase 1Unknown

A randomized, single-center, double-blind, placebo-controlled, first-in-human trial with single and multiple ascending doses to determine safety, tolerability, and pharmacokinetics of GRT7040 in healthy volunteers

Showing all 2 trials

Research Network

Common Treatments

  • Midazolam1
  • Grt7041 Mad1
  • Grt7041 Sad1

Active Sponsors

  • Grünenthal GmbH1
  • Gruenenthal GmbH1

Activity Timeline